Alliance for Multispecialty Research,Llc — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$5,764,520	187
2024	Research	$3,109,137	190
2023	Research	$805,904	19
2022	Research	$1,440,368	29
2021	Research	$619,477	77
2020	Research	$442,265	45
2019	Research	$723,293	59

Breakdown

Who paid Research payments · program years 2019–2025

Sanofi Pasteur Inc. $11,267,871 516 payments
Sanofi US Services Inc. $1,404,237 81 payments
Genzyme Corporation $232,857 9 payments

Studies the money was for Research payments · program years 2019–2025

A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older $3,572,452 56 payments
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older $1,503,753 39 payments
A Phase I, parallel, randomized, active-controlled, multi-center, dose-escalation study with early safety data reviews to assess safety and immunogenicity of a monovalent mRNA vaccine encoding influenza hemagglutinin in adults 18 years of age and older $1,455,468 32 payments
A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. $1,061,780 23 payments
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above $879,381 67 payments
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) $620,541 61 payments
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). $601,110 43 payments
VAN00001 Safety and Immunogenicity of an Investigational Meningococcal Group B Vaccine in Healthy Adults $448,630 26 payments
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older $325,057 8 payments
Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) in Children and Adolescents Aged 9 to 17 Years and Adults Aged 18 to 49 Years. $319,722 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.